AC 410
Alternative Names: AC-410Latest Information Update: 28 Jul 2018
At a glance
- Originator Ambit Biosciences Corporation
- Developer Daiichi Sankyo Company
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Janus kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Autoimmune-disorders in USA (PO)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Inflammation in USA (PO)
- 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company